Adicet Bio, Inc. Common Stock (1IJ)

Overview

Adicet Bio, Inc. stands out as a prominent player in the biotechnology sector, specifically focusing on the clinical stage development of innovative therapies. Founded in 2014 and headquartered in Boston, Massachusetts, the company is pioneering in the exploration and creation of allogeneic gamma delta T cell therapies. These advanced treatments are designed to target and combat a variety of autoimmune diseases as well as cancer, marking a significant advancement in the realm of immunotherapy. Adicet Bio, Inc.'s approach involves engineering gamma delta T cells with chimeric antigen receptors (CARs), aiming to achieve long-lasting activity and therapeutic efficacy in patients suffering from these challenging conditions.

Products and Services

• ADI-001

  ADI-001 represents the forefront of Adicet Bio, Inc.'s innovative efforts, being a pioneering product candidate within the company's portfolio. This allogeneic gamma delta T cell therapy is engineered to express a CAR that specifically targets CD20. Currently undergoing a Phase I clinical trial, ADI-001 is designed for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Its development symbolizes a promising advancement in the fight against lymphoma, offering a novel therapeutic option that harnesses the power of the immune system to target and eliminate cancer cells.

• ADI-270

  Expanding its reach in the domain of CAR T cell therapy, Adicet Bio, Inc. is also advancing ADI-270, a highly specialized armored gamma delta CAR T cell product candidate. This therapy is under development to target renal cell carcinoma, along with other CD70+ solid tumor and hematological malignancies indications. By focusing on these particular cancer cells, ADI-270 aims to offer a targeted, immunotherapy-based approach to treating cancer, underscoring Adicet Bio, Inc.'s commitment to addressing a wide range of cancer types with cutting-edge and personalized treatments.